The initiation of an SGLT2 inhibitor or a GLP-1 receptor agonist compared with a DPP-IV inhibitor was associated with lower CV events and death without increasing the overall incidence rate of severe safety outcomes, regardless of frailty status, Elisabetta Patorno, MD, DrPH , associate professor of medicine at Harvard Medical School and associate epidemiologist in the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Womens Hospital, and colleagues wrote
Received: Published: Version of record: Issue date: DOI:
Medicare coverage for GLP-1 medications is currently very limited unless you have a diagnosis thats not related to weight loss, says Dave Knapp, founder of On the Pen , a community education website about GLP-1s
Researchers interested in the fat-specific effects of peptides can explore the peptides for fat loss category , the fat burning peptides for men guide, and the FTPP peptide (adipotide) guide for compounds that specifically target adipose tissue through different mechanisms
doi: 10.2337/db10-1332 56 ElliottRMMorganLMTredgerJADeaconSWrightJMarksV